Concord Biotech working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024
420.48×420.48×267.39×331.17×
169.86×169.86×132.49×125.48×
159.68×159.68×123.94×150.39×
430.66×430.66×275.94×306.26×
1.07×0.98×1.26×1.35×
0.49×0.49×0.64×0.60×
1.03×1.03×0.66×0.86×
0.73×0.73×0.48×0.62×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CONCORDBIO₹1,230.60

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹12,874 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)—331.17267.39420.48420.48
Receivable Days (DSO)—125.48132.49169.86169.86
Payable Days (DPO)—150.39123.94159.68159.68
Cash Conversion Cycle (days)—306.26275.94430.66430.66
Working Capital Turnover—1.351.260.981.07
Asset Turnover—0.600.640.490.49
Cash Conversion (CFO/Net Income)—0.860.661.031.03
CFO/EBITDA—0.620.480.730.73
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.